Joseph C Lin

US Patent:

6703220, Mar 9, 2004

Filed:

Mar 24, 2000

Appl. No.:

09/535145

Inventors:

Michael S. German - San Francisco CA
Joseph Lin - San Francisco CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 1512

US Classification:

435 691, 435325, 4353201, 4352523, 536 235, 536 231

Abstract:

The present invention features a human neurogenin3 (Ngn3) polypeptide and nucleotide sequences encoding Ngn3 polypeptides. In a particular aspect, the polynucleotide is the nucleotide sequence of SEQ ID NO:1. In addition, the invention features isolated nucleic acid sequence comprising an Ngn3 promoter, as well as a polynucleotide sequences that hybridize under stringent conditions to SEQ ID NO:1. In related aspects the invention features expression vectors and host cells comprising polynucleotides that encode a human Ngn3 polypeptide. The present invention also relates to antibodies that bind specifically to a human Ngn3 polypeptide, methods for producing human Ngn3 polypeptides, methods for identifying -cell precursor cells expressing Ngn3, methods for using the Ngn3 gene and the Ngn3 polypeptide to alter cellular differentiation in culture or in vivo to produce new -cells to treat patients with diabetes mellitus, and identification of individuals at risk for diabetes by detecting alteration in Ngn3 coding and regulatory sequences and Ngn3 expression levels.

US Patent:

20110061115, Mar 10, 2011

Filed:

Jun 18, 2007

Appl. No.:

12/308351

Inventors:

Joseph H. Lin - Menlo Park CA, US
Judith A. Shizuru - Palo Alto CA, US

International Classification:

A01K 67/00
C12N 5/00
C12N 5/02
A61K 35/12
C12N 5/07

US Classification:

800 9, 435325, 435383, 424 937, 435354

Abstract:

Substantially enriched mammalian lung endothelial and epithelial progenitor cell populations are provided. Methods are provided for the isolation and in vivo differentiation of such lung progenitor cells. The progenitor cells are obtained from lung tissue, including fetal and adult tissues. The cells are useful in transplantation, for experimental evaluation, and as a source of lineage and cell specific products, including mRNA species useful in identifying genes specifically expressed in these cells, and as targets for the discovery of factors or molecules that can affect them.

US Patent:

20150239988, Aug 27, 2015

Filed:

Feb 25, 2015

Appl. No.:

14/631574

Inventors:

- Foster City CA, US
Joseph H. Lin - San Mateo CA, US
Victoria Smith - Burlingame CA, US
Maria Vaysberg - Los Altos CA, US

International Classification:

C07K 16/40
A61K 39/395
A61K 45/06

Abstract:

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).